An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)

NCT00248157 Phase 3 TERMINATED

This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802. During this extension study, all patients will receive open-label treatment of octreotide acetate in microspheres every 4 weeks for 2 years for the treatment of moderately severe to severe NPDR and low risk PDR.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	TERMINATED
Enrolment	105
Start date	2005-11
Completion	2006-05

Conditions

• Diabetic Retinopathy

Interventions

• Octreotide acetate in microspheres

Primary outcomes

• long-term safety and tolerability